Eric Lefkofksy has made a name for himself as one of the Chicago area’s most successful tech entrepreneurs. After having founded Groupon, an innovative company that uses the power of volume purchasing to get group discounts for people in disperse locations across the country, he went on to found a series of other highly successful companies. But then his wife was diagnosed with advanced breast cancer in 2013.
Over the course of the next year, Lefkofsky accompanied his wife to her medical appointments. He was distraught to find out that, often times, oncologists had less access to quality data than did truck drivers or salesmen. He was also surprised to discover the extent to which modern cancer treatments still take a one-size-fits-all approach. If companies like Amazon are capable of generating pages that are highly customized to a user’s preferences, why couldn’t oncology, with the billions and billions spent on it each year, do the same? He set out to research what the answers to those questions were.
Eventually, he came to the conclusion that no single package existed for oncological use that drew from all of the crucial sources of medical data and combined that data into a useful output. In 2016, Lefkofsy founded Tempus, a company dedicated to creating custom analytics for oncologists, enabling the most powerful information available to be put into the clinical setting, in real time.
Tempus makes use of many data sources, including electronic medical records and scientific research papers. But the most important source of the data that the Tempus system relies on is the human genome itself. Lefkofsky explains that the cost of sequencing a single person’s genome has dropped precipitously over the last 14 years. In the year 2003, when the first full human genome was sequenced, the cost was a whopping $100,000,000. Fast forward 14 years and that price tag has plummeted to just $5,000, a 20,000-fold decrease. Eric Lefkofksy projects that number will fall to just a couple hundred dollars in the coming decade.
At such low prices, it will become commonplace for people to have their genome sequenced. Tempus will make optimal use of this data.
Over the course of the past thirty years, Prof. Mikhail Blagosklonny has been striving towards contributing as much as possible in his lifetime to the fight against cancer. He has also been very dedicated to his research in the field of biogerontology or plainly put – the mechanisms of aging. Prof. Mikhail Blagosklonny has been working towards finding a way to slow down and possibly even reverse the process of aging.
- Mikhail Blagosklonny put a start to his journey in the world of science and medicine in his home country of Russia. There, he was a student at a renowned institution called First Pavlov State Medical University. The famous school is located in the second largest city in Russia – St. Petersburg. Prof. Mikhail Blagosklonny graduated from the First Pavlov with both a Ph. D. and an M.D. He majored in Experimental Medicine and Cardiology first, and then in Internal Medicine.
In 2002, Prof. Mikhail Blagosklonny traveled to the United States of America. In New York City, Prof. Mikhail Blagosklonny became a valued member of the New York Medical College where he taught Medicine for a few years. Prof. Mikhail Blagosklonny wished to focus on conducting medical and scientific research, and that prompted him to join another institution that would be able to make it possible for him – the Ordway Research Institute. Prof. Mikhail Blagosklonny was appointed to the position of senior scientists which he occupied for a few years as well. His research was sharply focused on the field of oncology. The research that Prof. Mikhail Blagosklonny was able to conduct at the Ordway Research Institute, however, had a number of restraints. The Institute was not able to support any further research In search of more options; Prof. Mikhail Blagosklonny moved on and took a position at the Roswell Park Cancer Institute. As the name of the institution denotes, Roswell Park is specialized in the research of cancer. Visit classroomvoices.org to read more about Mikhail.
- Mikhail Blagosklonny has been doing research at the Roswell Park Cancer Institute from 2009, and he is still an integral part of the Institute. He has also been able to expand upon his research, and so he has been doing research in biogerontology as well as further his research of the many types of cancer. Prof. Mikhail Blagosklonny is working with many esteemed researchers and scientists.
Along with his scientific and medical research, Prof. Mikhail Blagosklonny has been devoted to his work as an editor and editor in chief. The professor has been an editor in chief of Oncotarget along with one of his colleagues from the Roswell Park Cancer Institute. He has also been an editor of Cell Cycle and Aging – two other online medical journals. Prof. Mikhail Blagosklonny has also written a plethora of articles and papers on a variety of medical and scientific topics. His written work amasses to more than a hundred pieces. Most of them encompass the topics of biogerontology and oncology and talk about his research up until that point and the overall progression and future of his research. Read more on templeofthecave.com
Seattle Genetics is among the majority of the companies making interesting discoveries in the field of cancer research. Dr. Siegall, CEO of Seattle Genetics, has been ardent on enhancing treatment for cancer patients since starting his career in biomedical studies. He has led this innovative company for approximately two decades. Dr. Siegall’s hardwork and determination has greatly contributed to advancements in cancer research and therapies for cancer patients.
Siegall amassed many professional accomplishments since getting his Ph.D. in Genetics from George Washington University. His career started as a senior research investigator at the Bristol-Myers Squibb Pharmaceuticals Research Institute. Before becoming the staff and biotechnology fellow at the National Cancer Institute, he was promoted to being the principal scientist.
Seattle Genetics developed the first antibody-drug conjugates (ADCs) and ADCETRIS, which got approved by FDA in 2011. Currently, ADCETRIS is now available to cancer patients in more than 60 countries around the world. Siegall helped to fundraise over $1.2billion in both public and private funding. The funds were to finance Seattle Genetics in paving way for advanced cancer treatments using innovative technology.
Dr. Siegall was awarded the University of Maryland Alumnus of the Year for Math, Computer and Natural Sciences in 2013. In 2012, he was named the Pacific Northwest Ernst & Young Entrepreneur of the Year. These awards were meant to recognize his significant contributions to the medical and scientific communities. Siegall currently hold 15 patents and continues to search for new ways in medical research. He has published over 70 scientific articles and still shares his knowledge with the medical and scientific communities.
Clay Siegall is an enthusiast of science and technology. In 1998, he co-founded Seattle Genetics. Currently, he is the president, CEO and chairman of the board at Seattle Genetics. The company is growing since their stock price tripled in a span of 5 years. This growth is all because of Clay’s interest in drug development, scientific innovations, research and importantly helping patients.
The Seaport World Trade Center’s Pegs Boston interviewed Siegall concerning the future he envisioned for Seattle Genetics. He said that the company had made a couple of drugs SGN-CD33A and SGN-CD19A. The drugs are designed to target Leukemia cells and stabilize the bloodstream to enable the flushing out of cytotoxic agents.